Table 3.

Clinical outcomes according to time of regorafenib treatment initiation (pre- or post-inclusion of the ReDOS strategy in NCCN Guidelines), stratified by dose group

Clinical characteristic	Pre-inclusion of ReDOS in NCCN Guidelines (n = 310)		Post-inclusion of ReDOS in NCCN Guidelines (n = 393)
	Standard dosing (n = 244)	Flexible dosing (n = 66)	Standard dosing (n = 215)	Flexible dosing (n = 178)
Number of treatment cycles
Mean (SD)	2.7 (3.2)	2.3 (1.7)	3.1 (3.0)	3.3 (3.2)
Median (range)	2.0 (1.0–27.0)	2.0 (0.5–11.0)	2.0 (1.0–26.0)	2.0 (0.5–20.0)
Patients reaching the third treatment cycle, n (% [95% CI])	90 (36.9 [30.8, 43.3])	23 (34.8 [23.5, 47.6])	99 (46.0 [39.2, 53.0])	80 (44.9 [37.5, 52.6])

CI, confidence interval; NCCN, National Comprehensive Cancer Network; SD, standard deviation